SG Americas Securities LLC Buys 25,058 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

SG Americas Securities LLC lifted its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 28.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 112,291 shares of the company’s stock after buying an additional 25,058 shares during the period. SG Americas Securities LLC’s holdings in Mersana Therapeutics were worth $161,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. US Bancorp DE bought a new position in Mersana Therapeutics during the 3rd quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Mersana Therapeutics during the third quarter valued at approximately $34,000. Intech Investment Management LLC bought a new position in shares of Mersana Therapeutics in the third quarter worth approximately $52,000. Quarry LP purchased a new position in shares of Mersana Therapeutics in the third quarter worth $57,000. Finally, Avanza Fonder AB bought a new stake in Mersana Therapeutics during the 4th quarter valued at $81,000. Institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $0.75 on Monday. Mersana Therapeutics, Inc. has a 1 year low of $0.49 and a 1 year high of $6.28. The stock has a market capitalization of $92.65 million, a P/E ratio of -1.23 and a beta of 1.39. The company’s 50-day moving average is $1.33 and its 200 day moving average is $1.68. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $7.53 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business’s revenue for the quarter was up 63.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.35) EPS. On average, sell-side analysts expect that Mersana Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MRSN. Wedbush reissued an “outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Mersana Therapeutics in a report on Friday, January 10th. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday. They issued an “outperform” rating on the stock. Finally, Citigroup initiated coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Mersana Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $5.57.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.